The benefits of inhaled biotherapeutics include targeted delivery, reduced toxicity and fewer side effects. DPIs offer portability, ease of use, and potential home-based treatment, enhancing patient experience. These advantages make DPIs an appealing option for lung-based therapies, especially for local targets. While small molecules dominate clinical trials, biologics constitute a significant portion of active pharmaceutical ingredients (APIs) tested for lung delivery.

This article discusses the formulation of biotherapeutics as dry powder inhalers (DPIs) for inhaled delivery, providing several advantages over injectable forms. Read to learn more about the growing market for DPIs, particularly inhaled biotherapeutics such as monoclonal antibodies (mAbs), oligonucleotides, and proteins.

You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center